DC vaccines appear to be safe and may improve outcomes in some patients with advanced/relapsed NSCLC, particularly when combined with chemotherapy or checkpoint inhibitors in early trials, but results from various studies and meta-analyses are mixed. Check more about Dendritic Cell Therapy for non small cell lung cancer! The transition to routine practice has not occurred due to the limited availability of high-quality randomized data—more rigorous combination trials (and agreed-upon endpoints for OS/PFS) are needed before this can be called a breakthrough. 

How effective is dendritic cell therapy in improving overall survival and progression-free survival in patients with advanced or recurrent non-small cell lung cancer, particularly when used in combination with standard treatments such as immune checkpoint inhibitors or chemotherapy?